I haven't followed this as closely as I should have but what I'm gathering is that CHRS's victory of the '135' patent opens the gate for their approval and rollout of Neulasta (Amgen) and doesn't move the timeline on Abbvie's Humira.
They expect their Neulasta Biosim to be approved shortly. We'll see how they partner or get acquired to get a feel of what he market's worth.
Market Data 
Markets 
AI
